GlassScriptPhysician profile
John Rocco Robilotto
NPI 1356420798
$5,624.95
in general payments reported to CMS, 2019-2025
18 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $94.71 · 2021: $548 · 2022: $1,289 · 2023: $1,406 · 2024: $905 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134 · Consulting Fee: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.99 |
| Consulting Fee | $193.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,085.57 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $1,046.21 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $979.46 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $787.57 | 2019-2025 | Myday Contact Lens, Onefit Contact Lens |
| Johnson & Johnson Vision Care, INC. | $771.02 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $203.56 | 2021-2025 | Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.94 | 2019-2021 | |
| Allergan, INC. | $141.16 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $133.82 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $89.86 | 2019 | |
| Sight Sciences, INC. | $42.30 | 2022-2023 | Tearcare System |
| Visioneering Technologies, INC. | $40.00 | 2019 | |
| Mylan INC. | $27.70 | 2025 | Tyrvaya |
| Abbvie INC. | $27.53 | 2024 | |
| Dompe US, INC. | $22.95 | 2023 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $20.51 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $20.11 | 2021 | |
| Shire North American Group INC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robilotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.